Literature DB >> 29266320

Network on veterinary medicines initiated by the European Federation For Pharmaceutical Sciences.

J P Mochel1, E Tyden2, K Hellmann3, J C Vendrig4, S Şenel5, L Dencker6, R T Cristina7, H Linden8, I Schmerold9.   

Abstract

The European Federation for Pharmaceutical Sciences (EUFEPS) was founded 25 years ago by more than 20 national pharmaceutical societies and faculty members. As a pan-European organization, it brings together pharmaceutical societies as well as academic, industrial and regulatory scientists engaged in drug research and development, drug regulation and education of professionals working in these fields. EUFEPS represents pharmaceutical sciences in Europe and is recognized as such by both the European Commission and the European Medicines Agency. EUFEPS cooperates with the European Federation of Pharmaceutical Industries and other European organizations and maintains global connections with agencies such as the US Food and Drug Administration and the American Association of Pharmaceutical Scientists. EUFEPS has established specified networks forming the basis of its activities. The creation of a Network on Veterinary Medicines is prompted by the manifold problems resulting from the use of veterinary drugs and its inherent interconnections with human medicine, environmental and public health. A long-term goal of this initiative was to expand the spectrum of available therapeutics for use in animals, including the development of innovative delivery systems.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  EUFEPS; network; pharmaceutical sciences; veterinary medicines

Mesh:

Substances:

Year:  2017        PMID: 29266320     DOI: 10.1111/jvp.12472

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  1 in total

1.  Regulatory Science and Innovation Programme for Europe (ReScIPE): A proposed model.

Authors:  Philip A Hines; Richard H Guy; Angela Brand; Anthony J Humphreys; Marisa Papaluca-Amati
Journal:  Br J Clin Pharmacol       Date:  2019-10-17       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.